Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TELSTAR-2
NL-OMON59336Phase 3Recruiting
- Sponsor
- University of Twente
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of midazolam in status epilepticus (SE) (2 arms), sponsored by University of Twente. Primary endpoint: Functional recovery at 6 months. Started Apr 2025; status: recruiting.
02
Drugs
midazolam
03
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on NL-OMON59336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59336.